Posted by Michael Wonder on 15 Jan 2023
Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
13 January 2023 - People living with type 2 diabetes can now take Rybelsus, the first and only oral glucagon-like peptide-1 analogue, along with diet and exercise, as initial therapy to help lower their A1C.
The US FDA has approved a label update for Rybelsus (semaglutide) 7 mg & 14 mg tablets, allowing use as a first-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment.
